Clinical Trial Update: Adjuvant Toripalimab Plus Chemotherapy for EGFR/ALK Mutation Negative Stage II-IIIB(N2) NSCLC (LungMate-008) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating adjuvant toripalimab plus chemotherapy for EGFR/ALK mutation-negative stage II-IIIB(N2) non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Chemotherapy (chemotherapy)
• Toripalimab (Toripalimab)

Snippet

Sponsor: Shanghai Pulmonary Hospital, Shanghai, China | Conditions: Non Small Cell Lung Cancer | Phase 3 | Status: NOT_YET_RECRUITING